RNA, U2 small nuclear 56, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU2-56P profile across patient tissues and cancer cell-line models. RNU2-56P expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RNU2-56P is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, RNU2-56P RNA expression shows 6,355 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight BLCA, HNSC, and COAD as cancer lineages where RNU2-56P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU2-56P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU2-56P survival associations across molecular data types. RNU2-56P RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU2-56P RNA expression–survival associations across cancer types. High RNU2-56P expression shows unfavorable associations in BLCA, LIHC, KIRC, KIRP, CESC and COAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RNU2-56P RNA expression.
This table summarizes RNU2-56P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU2-56P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU2-56P shows higher tumor expression in HNSC and LUAD. The HNSC box plot shows higher RNU2-56P RNA expression in tumor versus normal tissue (log2 FC = +0.061, t-test p = .006).
This table shows molecular features associated with RNU2-56P in patient tissues and cancer cell lines. In patient samples, RNU2-56P shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
